TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
23 04 2019
Historique:
accepted: 16 01 2019
received: 20 12 2018
pubmed: 31 1 2019
medline: 29 10 2019
entrez: 31 1 2019
Statut: ppublish

Résumé

The telomeric protein TRF2 is overexpressed in several human malignancies and contributes to tumorigenesis even though the molecular mechanism is not completely understood. By using a high-throughput approach based on the multiplexed Luminex X-MAP technology, we demonstrated that TRF2 dramatically affects VEGF-A level in the secretome of cancer cells, promoting endothelial cell-differentiation and angiogenesis. The pro-angiogenic effect of TRF2 is independent from its role in telomere capping. Instead, TRF2 binding to a distal regulatory element promotes the expression of SULF2, an endoglucosamine-6-sulfatase that impairs the VEGF-A association to the plasma membrane by inducing post-synthetic modification of heparan sulfate proteoglycans (HSPGs). Finally, we addressed the clinical relevance of our findings showing that TRF2/SULF2 expression is a worse prognostic biomarker in colorectal cancer (CRC) patients.

Identifiants

pubmed: 30698737
pii: 5304306
doi: 10.1093/nar/gkz041
pmc: PMC6468246
doi:

Substances chimiques

Heparan Sulfate Proteoglycans 0
TERF2 protein, human 0
Telomeric Repeat Binding Protein 2 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
Heparin 9005-49-6
Sulfotransferases EC 2.8.2.-
SULF2 protein, human EC 3.1.6.-
Sulfatases EC 3.1.6.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3365-3382

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Front Oncol. 2013 Mar 15;3:48
pubmed: 23509004
Invest Ophthalmol Vis Sci. 2012 Oct 03;53(11):6810-7
pubmed: 22956610
J Intern Med. 2013 Feb;273(2):114-27
pubmed: 23216836
Nature. 2013 Feb 28;494(7438):502-5
pubmed: 23389450
Neoplasia. 2005 Nov;7(11):1001-10
pubmed: 16331886
Cell. 1998 Feb 6;92(3):401-13
pubmed: 9476899
Clin Cancer Res. 2003 Mar;9(3):1105-11
pubmed: 12631614
Oncoimmunology. 2014 Jan 1;3(1):e27358
pubmed: 24701373
Trends Biochem Sci. 2015 May;40(5):275-85
pubmed: 25845889
Nat Genet. 2005 Oct;37(10):1063-71
pubmed: 16142233
EMBO Rep. 2013 Apr;14(4):356-63
pubmed: 23429341
Expert Opin Ther Targets. 2010 Sep;14(9):935-49
pubmed: 20629619
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Cell Res. 2011 Jul;21(7):1028-38
pubmed: 21423270
Cell Rep. 2014 Nov 6;9(3):1047-60
pubmed: 25437559
Mol Biol Cell. 2010 Mar 1;21(5):687-90
pubmed: 20185770
BMC Biochem. 2006 Jan 17;7:2
pubmed: 16417632
Nucleic Acids Res. 2014 Mar;42(5):2945-57
pubmed: 24335081
J Biol Chem. 2018 Sep 7;293(36):13786-13794
pubmed: 29187597
Front Oncol. 2014 Jul 24;4:195
pubmed: 25105093
Nat Struct Mol Biol. 2007 Feb;14(2):147-54
pubmed: 17220898
Mol Cell. 2013 Mar 7;49(5):825-37
pubmed: 23473601
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16434-9
pubmed: 21903926
PLoS One. 2016 Feb 16;11(2):e0148911
pubmed: 26882224
Nat Cell Biol. 2013 Jul;15(7):818-28
pubmed: 23792691
Curr Biol. 2008 Oct 14;18(19):1489-94
pubmed: 18818083
J Biol Chem. 1996 Mar 29;271(13):7788-95
pubmed: 8631822
J Biol Chem. 2008 Oct 10;283(41):27724-35
pubmed: 18687675
J Biol Chem. 2002 Nov 15;277(46):43763-70
pubmed: 12226097
Eur J Cancer. 2006 Aug;42(12):1881-8
pubmed: 16750909
Nat Rev Mol Cell Biol. 2005 Jul;6(7):530-41
pubmed: 16072037
J Biol Chem. 2006 Feb 24;281(8):4969-76
pubmed: 16377625
Glia. 2014 Oct;62(10):1687-98
pubmed: 24909307
J Biol Chem. 2004 Feb 13;279(7):5604-11
pubmed: 14645250
J Biol Chem. 2010 Jan 8;285(2):1457-67
pubmed: 19864690
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Nucleic Acids Res. 2017 Feb 28;45(4):1820-1834
pubmed: 27923994
Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19
pubmed: 24332926
J Biol Chem. 2003 Sep 12;278(37):35693-701
pubmed: 12824159
Cell Res. 2011 Jul;21(7):1013-27
pubmed: 21423278
Carbohydr Res. 2008 Aug 11;343(12):2018-23
pubmed: 18334249
ChemMedChem. 2012 Dec;7(12):2144-54
pubmed: 23097341
Methods Enzymol. 2006;416:243-53
pubmed: 17113870
Oncotarget. 2016 Jul 12;7(28):44236-44251
pubmed: 27329590
Biochem Soc Trans. 2009 Dec;37(Pt 6):1201-6
pubmed: 19909247
Immunol Cell Biol. 2008 Oct;86(7):598-607
pubmed: 18626488
Breast Cancer Res Treat. 2011 Jun;127(3):623-30
pubmed: 20625812
Biochemistry. 2008 Oct 28;47(43):11174-83
pubmed: 18826258
Genes Dev. 2007 Jan 15;21(2):206-20
pubmed: 17234886
Front Oncol. 2014 Jan 14;3:331
pubmed: 24459635
Trends Biochem Sci. 2014 Jun;39(6):277-88
pubmed: 24755488
Nat Cell Biol. 2010 Dec;12(12):1205-12
pubmed: 21057505
Front Oncol. 2014 Jul 02;4:131
pubmed: 25072019
Stem Cells. 2014 Aug;32(8):2111-22
pubmed: 24740933
Nat Rev Genet. 2014 Jul;15(7):491-503
pubmed: 24913665
Mol Pharmacol. 2001 Nov;60(5):981-8
pubmed: 11641426

Auteurs

Pasquale Zizza (P)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Roberto Dinami (R)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Manuela Porru (M)

SAFU, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Chiara Cingolani (C)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Erica Salvati (E)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Angela Rizzo (A)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Carmen D'Angelo (C)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Eleonora Petti (E)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Carla Azzurra Amoreo (CA)

Pathology, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Marcella Mottolese (M)

Pathology, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Isabella Sperduti (I)

Department of Biostatistics Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Angela Chambery (A)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università della Campania Luigi Vanvitelli, via Vivaldi 43, 80100 Caserta.

Rosita Russo (R)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università della Campania Luigi Vanvitelli, via Vivaldi 43, 80100 Caserta.

Paola Ostano (P)

Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, via Malta 3, 13900 Biella.

Giovanna Chiorino (G)

Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, via Malta 3, 13900 Biella.

Giovanni Blandino (G)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Andrea Sacconi (A)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Julien Cherfils-Vicini (J)

Université Côte d'Azur, CNRS UMR 7284/INSERM U108, Institute for Research on Cancer and Aging, Nice (IRCAN), Medical School, Nice, France.

Carlo Leonetti (C)

SAFU, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Eric Gilson (E)

Université Côte d'Azur, CNRS UMR 7284/INSERM U108, Institute for Research on Cancer and Aging, Nice (IRCAN), Medical School, Nice, France.
Department of Medical Genetics, Archet 2 Hospital, CHU of Nice, France.

Annamaria Biroccio (A)

Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH